Dr Georgia McCaughan

Presentations

Clinical

Established a dedicated Myeloma Clinic for new referrals of patients with plasma cell dyscrasias including multiple myeloma, smouldering myeloma, MGUS and AL amyloidosis.

Clinical Trials and Registry

Entered and maintain up to date data for all St Vincent’s patients diagnosed with myeloma from November 2017 onwards in the Australian and New Zealand Myeloma and Related Diseases Registry. Contributed additional data for IMPROVE study examining intravenous immunoglobulin use.
Selected as a site for ALL-G trials FRAIL-M (frailty stratified therapy for newly diagnosed MM), IRIL (isatuxumab rescue for patients with inadequate response to lenalidomide/dexamethasone) and SeaLAND (addition of selinexor to lenalidomide in maintenance)
Selected as a site for DREAMM8: belantamab-pomalidomide-dexamethasone versus pomalidomide-bortezomib-dexamethasone.
Selected as a site for BelaCarD, an AMARC study evaluating belantamab mafodotin and carfilzomib in Relapsed/Refractory multiple myeloma
Pursued and signed CDA with Celgene/BMS
At feasibility stage with other pharmaceutical companies regarding immunotherapy trials (confidential discussions)

Community Engagement

AMaRC (Australasian Myeloma Research Consortium) Research Advisory Group Member
ALL-G Myeloma Working Group Scientific Meeting and Group Writing Lead
MM23 (SEALAND) – Phase III Randomised Trial of Selinexor and Lenalidomide Maintenance – Trial Management Committee
Australia/New Zealand Myeloma Ambassador Program
Wrote protocols for EVIQ: Weekly carfilzomib/dexamethasone; pomalidomide/bortezomib/dexamethasone; GRIFFIN RVD; RVD-lite; RVD-SWOG S0777.

Publications

McCaughan G, Jarvis, S and Joseph J. Abnormal Coagulation Profile in Monoclonal Gammopathy of Undetermined Significance. *Accepted for publication in Pathology.
McCaughan G, Verma A, Ling S, Lavee O, Moore J, Bryant A. Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres. Bone Marrow Transplant (2020) https://doi.org/10.1038/s41409-020-01086-9
Withers, B* and McCaughan G*, Hayward C, Kotlyar E, Jabbour A, Rainer S, De Angelis E, Horvath N, Dogan A, MacDonald P, Moore J. Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort. Internal Medicine Journal. DOI: https://doi.org/10.1111/imj.15072 *Shared first authorship
McCaughan, G., Ma, D. & Moore, J. Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01025-8
Di Ciaccio* and G. McCaughan*, J Trotman, P. J. Ho, C. Cheah, S. Gangatharan, J. Wight, M. Ku, H. Quach, R. Gasiorowski, M. N. Polizzotto, H. M. Prince, S. Mulligan, C. S. Tam, G. Gregory, G. Hapgood, A. Spencer, M. Dickinson, M. Latimer, A. Johnston, T. Armytage, C. Lee, T. Cochrane, L. Berkhahn, R. Weinkove, R. Doocey, S. J. Harrison, N. Webber, H. Lee, S. Chapman, B. A. Campbell, S. D. J. Gibbs and N. Hamad. Australian and New Zealand Consensus Statement on the Management of Lymphoma, Chronic Lymphocytic Leukaemia and Myeloma During the COVID-19 Pandemic. Internal Medicine Journal. DOI: 10.1111/imj.14859

*Shared first authorship

Conference Presentations

2020
American Society of Haematology Conference, 2020. ‘Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study’.
Received ASH Achievement award for this abstract.

2020
HSANZ Baikie Symposium, 2020. ‘Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study’.

Other Ongoing Research Projects

PreEEMPT study: recruitment commenced

Collaboration with the Garvan Institute of Medical Research and University of New South Wales (Prof Peter Croucher, Prof John Murray, Prof Maurice Pagnucco, A/Prof John Moore, A/Prof Tri Phan): Predicting time to Environment-dependent Emergence of Myeloma in Patients (PreEEMPT).
Co-investigator on successful UNSW Futures Institute Grant for this project ($514,217)

Management of biochemical relapse in myeloma patients – an Australian and New Zealand experience. Project through the MRDR.

Contact us